Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Actavis plc (ACT) Manipulating Patients to Use New Alzheimer’s Drug: NY AG’s Office

Actavis plc (NYSE:ACT) is in hot water with the New York Attorney General’s office over practices they feel are manipulative of patients. As Meg Tirrell reported on CNBC today, the drug company is employing a practice called “hard switching” with patients currently on their existing Alzheimer’s drug Namenda, the patent on which is about to expire.


 “This is a lifestyle management technique that pharma companies use a lot. However the New York Attorney General’s office is taking issue with what Actavis is doing here, saying this is manipulative to patients, especially to elderly patients with Alzheimer’s. It’s basically taking away that other, potentially cheaper generic copy when that goes generic next year, and trying to switch them onto a more expensive product, which they’ll have no choice to, because they’re stopping manufacturing the first product,” Tirrell said.

Actavis plc (NYSE:ACT)’s new Alzheimer’s drug Namenda XR, which is taken once daily as opposed to twice daily with the current version of the drug, will have new patents protecting it, potentially allowing Actavis plc (NYSE:ACT) to continue reaping the benefits of the near monopoly they currently enjoy, if they can coerce patients to switch to it.

In the lawsuit, New York Attorney General Eric Schneiderman is attempting to force Actavis plc (NYSE:ACT), along with its subsidiary Forest Labs, to halt their planned discontinuation of the original Namenda, and subsequent attempt to maintain their monopoly through forced switching to Namenda XR. Schneiderman is also seeking civil damages and penalties.

Despite the lawsuit, Actavis plc (NYSE:ACT) is actually up a healthy 1.67% today. As Tirrell reports, this is not related to the lawsuit, but rather the fact that Actavis plc (NYSE:ACT) continues to be rumored as a potential takeover target of Pfizer Inc. (NYSE:PFE)’s if another attempt at acquiring their number one target, AstraZeneca plc (ADR) (NYSE:AZN), fails to come to fruition.

Actavis plc (NYSE:ACT) is up over 10% throughout the last month as the rumors first started to swell, and up 42% for the year to close today at $238.76.

Disclosure: none

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!